Lexicon Pharmaceuticals Inc. is a biopharmaceutical company that is focused on developing and commercializing pharmaceutical products using small molecule drug candidates. Their Phase III clinical trials for its treatment of heart failure and type 1 diabetes with Sotagliflozin are complete, while the company's new LX9211 product is in Phase II clinical development. Lexicon Pharmaceuticals has entered into strategic agreements and licensing arrangements with leading biotech and pharmaceutical companies like Bristol-Myers Squibb Company and Genentech Inc.